13F Holdings
中文EN

NAMS NewAmsterdam Pharma Co N.V.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1936258 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-26.4%
TTM net income YoY7.3%
TTM EPS YoY17.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-900.1%
Net margin-789.9%
FCF margin-581.6%
EBITDA margin-899.0%

Returns

ROE-30.2%
ROA-27.8%
ROIC (approx.)-92.8%
Asset turnover0.04x

Leverage & solvency

Liabilities / assets8.3%
Debt / equity0.00x
Current ratio11.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue1.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31 · USDFY20242024-12-31 · USDFY20232023-12-31 · USDFY20222022-12-31 · EURFY20212021-12-31 · EUR
Income statement
Revenue$22.50M$45.56M$14.09M97.50M—
R&D expense$141.83M$151.41M$159.42M82.23M25.03M
SG&A expense$106.35M$70.45M$37.63M22.23M4.80M
Operating income-$225.68M-$176.29M-$182.97M-67.56M-29.84M
Interest expense———271,000216,000
Pretax income-$203.82M-$241.60M-$176.91M-78.05M-28.60M
Income tax—-$1,000$27,000——
Net income-$203.82M-$241.60M-$176.94M-78.05M-28.60M
EBITDA-$225.46M-$176.18M-$182.92M-67.49M-29.82M
EPS (basic)-1.72-2.56-2.15-1.97-1.21
EPS (diluted)-1.72-2.56-2.15-1.97-1.21
Weighted avg. shares (diluted)118.42M94.36M82.16M18.97M11.09M
Balance sheet
Cash & equivalents$490.00M$771.74M$340.45M438.52M53.09M
Short-term investments$146.24M$62.45M———
Current assets$675.70M$863.41M$346.79M448.13M58.87M
PP&E, net$383,000$242,000$46,000144,000190,000
Intangibles———83.16M—
Total assets$769.28M$864.62M$347.10M531.58M59.78M
Current liabilities$85.79M$106.92M$49.90M35.46M9.88M
Total liabilities$85.85M$107.12M$58.70M$48.43MUSD9.99M
Shareholders' equity$683.43M$757.50M$288.39M$430.07MUSD-$113.82MUSD
Shares outstanding114.40M108.06M82.47M81.56M11.33M
Cash flow statement
Operating cash flow-$147.78M-$158.56M-$141.22M7.97M-25.16M
Capital expenditure$246,000$672,000$24,00013,00020,000
Free cash flow-$148.03M-$159.24M-$141.24M7.96M-25.18M
Investing cash flow-$174.92M-$62.85M-$24,000715,000-20,000
Financing cash flow$29.52M$659.51M$8.91M375.18M68.99M
Depreciation & amortization$220,000$113,000$49,00072,00014,000
Stock-based compensation$59.42M$33.62M$24.57M3.92M1.05M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.